Top Stories
Kennedy Sidelining of US Advisory Panel Delays Updates to Cancer Screening Guidelines
The sidelining by HHS Secretary Robert F. Kennedy Jr. of the U.S. Preventive Services Task Force is delaying updates to cancer screening guidelines for breast, lung, colorectal, and cervical cancers, according to Reuters. The 16-member panel, established in 1984, has not met since March 2025, with three consecutive planned meetings cancelled and no replacements named for five members whose terms expired in December 2025. Under the Affordable Care Act, screening tests that receive USPSTF grade A or B recommendations must be covered at no cost to patients, making the panel's work directly consequential for cancer early detection. Notably, the FDA has since approved self-collected HPV tests, but the task force has been unable to evaluate them for a coverage recommendation. In March 2026, 19 U.S. senators sent a letter urging Kennedy to support the panel's work. The disruption could delay guideline modernization at a time when new screening technologies and expanded age-range recommendations are under active review. Screening technology developers gain time to build evidence Patients and insurers face uncertainty over coverage of newer cancer screening tools
AstraZeneca Reports Win in Liver Cancer
AstraZeneca reported a win in liver cancer treatment, according to Endpoints News, though specific trial details and endpoints were not disclosed in the available reporting. This development reinforces AstraZeneca's position in oncology drug development, particularly in liver indications where hepatocellular carcinoma patients face limited treatment options beyond first-line atezolizumab-bevacizumab and sorafenib. AstraZeneca's existing liver cancer portfolio includes tremelimumab plus durvalumab (STRIDE regimen), which received FDA approval for unresectable HCC. AstraZeneca strengthens its oncology portfolio in liver cancer Competing HCC therapies face a more crowded field
Telomir Advances Triple-Negative Breast Cancer Program with FDA Filing
Telomir Pharmaceuticals submitted an IND application to the FDA for Telomir-1, targeting advanced and metastatic triple-negative breast cancer (TNBC), according to Pharmaceutical Technology. The filing represents a critical milestone for the company as it seeks to enter the competitive TNBC space, where patients face limited treatment options and poor prognosis. TNBC is estimated to account for approximately 15% of all breast cancers according to published epidemiological data, and disproportionately affects younger women with higher recurrence rates. Telomir positions itself to compete in the high-need TNBC market where established players like Gilead Sciences with Trodelvy and Roche with Tecentriq combinations currently dominate. The FDA filing timing suggests potential Phase 1 initiation by late 2026, putting Telomir on track to generate initial safety data before competitors advance next-generation TNBC therapies.
Head and Neck Cancer Market Set for $4.5B Expansion Through 2034
The head and neck squamous cell carcinoma (HNSCC) market will reach $4.5 billion across 8 major markets by 2034, growing at an 8.4% CAGR, according to GlobalData analysis reported by Pharmaceutical Technology. This growth trajectory positions HNSCC as an increasingly attractive target for pharma investment, particularly as immunotherapy combinations gain traction in both first-line and recurrent settings. Companies with established HNSCC franchises like Merck with Keytruda and Bristol Myers Squibb with Opdivo stand to capture significant market expansion. The projected growth reflects both increasing incidence rates and the introduction of higher-priced combination therapies. Current market leaders will need to defend their positions against emerging ADC therapies and novel targeted agents entering clinical development. According to the GlobalData analysis, the 8.4% growth rate positions HNSCC among the faster-growing solid tumor markets, making it a priority indication for portfolio expansion.
Pipeline Watch
The FDA granted Fast Track designation to CTIM-76 for treating platinum-resistant ovarian cancer, according to CancerNetwork. This designation accelerates development timelines for a patient population with limited treatment options and poor prognosis. Fast Track status enables more frequent FDA meetings and potential priority review.
Institut de Recherches Internationales Servier launched a recruiting trial (NCT06465953) testing ivosidenib monotherapy versus azacitidine in hypomethylating agent-naive myelodysplastic syndrome patients with IDH1 mutations, per ClinicalTrials.gov. The study targets an underserved MDS subset where IDH1 inhibition could provide first-line treatment advantages.
A Phase 2 trial is evaluating defactinib combined with avutometinib in diffuse gastric cancer, according to CancerNetwork. The dual inhibition approach targets both FAK and RAS pathway signaling, potentially addressing resistance mechanisms in this aggressive gastric cancer subtype with limited targeted therapy options.
A Journal of Clinical Oncology study examined how treatment switching and subsequent therapies confound overall survival estimates in the PHAROS trial, per JCO Table of Contents. The analysis underscores challenges in interpreting OS endpoints when patients cross over to experimental arms or receive multiple subsequent treatments.
Competitive Landscape
Telomir's IND filing for advanced TNBC puts it against established leaders, per Pharmaceutical Technology. Gilead Sciences maintains TNBC leadership with Trodelvy's strong commercial uptake while newer entrants face the challenge of differentiation in an increasingly crowded space.
| Company | Drug | Status |
|---|---|---|
| Gilead | Trodelvy | Approved |
| Roche | Tecentriq combo | Approved |
| Telomir | Telomir-1 | IND Filed |
The projected $4.5B HNSCC market expansion through 2034 primarily benefits current immunotherapy leaders, according to Pharmaceutical Technology analysis. Merck and BMS are best positioned with established Keytruda and Opdivo franchises to capture the majority of this 8.4% annual growth.
CTIM-76's Fast Track status in platinum-resistant ovarian cancer reflects FDA's continued focus on accelerating treatments for high-unmet-need populations, per CancerNetwork. This regulatory support creates competitive advantages for companies targeting similar resistant cancer subtypes.
The prolonged inactivity of the USPSTF under HHS Secretary Kennedy's tenure creates uncertainty for companies developing novel cancer screening technologies, per Reuters. Without updated grade A or B recommendations, new tests such as self-collected HPV screening cannot secure mandated no-cost coverage under the ACA, potentially delaying market access and commercial adoption.
Forward Looking
- USPSTF reconstitution and resumption of meetings will determine timeline for updated cancer screening coverage recommendations, particularly for self-collected HPV tests and any expanded screening age ranges under review
- Telomir-1 Phase 1 data expected in H2 2027 will determine its competitive positioning against Trodelvy and other TNBC therapies.
- HNSCC market consolidation likely as the $4.5B opportunity attracts more ADC and targeted therapy investments through 2034.
- CTIM-76 Fast Track status suggests potential accelerated approval pathway if Phase 2 data demonstrate meaningful clinical benefit.
- Treatment switching analysis methodologies will become increasingly important as more oncology trials allow crossover designs.